Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: TAK-881, SC Investigational Needle Sets; Biological · Device
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Squamous Non Small Cell Lung Cancer
Interventions: HLX10, carboplatin and nab paclitaxel, Placebo; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: NSCLC
Interventions: GI-4000; Biological
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mucopolysaccharidosis VI
Interventions: N-acetylgalactosamine 4-sulfatase; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Novato, California

Conditions: Ocular Graft vs Host Disease, Dry Eye
Interventions: rhDNase I, Vehicle; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting
Interventions: RTL1000 (recombinant T cell receptor ligand), RTL1000 Placebo; Drug
Lead sponsor: Artielle ImmunoTherapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 6
States / cities: New Haven, Connecticut • Indianapolis, Indiana • Kansas City, Kansas + 3 more

Conditions: Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions: Half normal saline, Low Dose rhCC10, High dose rhCC10; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 24 Weeks to 29 Weeks
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts • Springfield, Massachusetts

Conditions: COVID-19
Interventions: Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283; Drug
Lead sponsor: Marcel Curlin; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Hemophilia A
Interventions: rFVIIIFc; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Los Angeles, California • Sacramento, California • Waltham, Massachusetts + 2 more

Conditions: HIV Infections
Interventions: EP HIV-1043, EP HIV-1090; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Rochester, New York

Conditions: Stroke, Brain Infarction
Interventions: Eptifibatide; Drug
Lead sponsor: Arthur Pancioli; Other
Eligibility: 18 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Edgewood, Kentucky • Florence, Kentucky • Fort Thomas, Kentucky + 1 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: HIV Infections
Interventions: ALVAC-HIV MN120TMGNP (vCP300), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Haemostasis, Healthy
Interventions: warfarin, eptacog alfa (activated), placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Influenza
Interventions: Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Gingival Recession, Platelet Derived Growth Factor
Interventions: Root coverage procedures; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
Interventions: Recombinant Fowlpox-TRICOM Vaccine, Recombinant Fowlpox GM-CSF Vaccine Adjuvant, Therapeutic Conventional Surgery, Pharmacological Study, Laboratory Biomarker Analysis; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Insulin-like Growth Factor-1 Deficiency
Interventions: NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 5 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Acute Kidney Injury Due to Sepsis
Interventions: Recombinant human alkaline phosphatase, Placebo; Biological · Other
Lead sponsor: AM-Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 16
States / cities: Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, methotrexate, thiotepa, radiation therapy; Biological · Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hemophilia A
Interventions: OBI-1; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 6 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Lymphoma, Non-Hodgkin
Interventions: recombinant human interleukin 21 and rituximab; Drug
Lead sponsor: ZymoGenetics; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

COVID-19 Reactogenicity

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)

PROPACT: Retrospective Prophylaxis Patient Case Collection

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Recombinant Human Platelet-derived Growth Factor in Combination With Collagen Matrix

Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma